RICHARD D. PETERSON - Corporate Board Profile

UNIVERSAL INSURANCE HOLDINGS, INC.

Filing Date	Source Excerpt
2014-04-23	Richard D. Peterson is a new director nominee this year. ... Mr. Peterson's executive leadership, financial and accounting knowledge and general business acumen will make him a valued addition to our Board.
2015-04-15	Richard D. Peterson has been a director of the Company since 2014. ... The Audit Committee members are Darryl L. Lewis, Richard D. Peterson and Ozzie A. Schindler, each of whom was determined by the Board to be independent under the applicable rules of the SEC and NYSE. Mr. Schindler serves as chairman of the Audit Committee. ... The Compensation Committee consists of Darryl L. Lewis, Richard D. Peterson and Michael A. Pietrangelo, each of whom was determined by the Board to be independent under the applicable rules of the SEC and NYSE. ... Director Summary Compensation Table: Richard D. Peterson Fees Earned or Paid in Cash ($) 48,639, Option Awards ($) 134,424, Total ($) 183,063.
2016-04-29	Richard D. Peterson became a director of the Company in 2014. Mr. Peterson has over 20 years of experience in the areas of executive management, finance and accounting. Since 2015, Mr. Peterson has served as Chief Financial Officer of Novan, Inc., a privately-held pharmaceutical company. Mr. Peterson served as Executive Vice President, Chief Financial Officer and Treasurer of Medicis Pharmaceutical Corporation from 1995 to 2012. Mr. Peterson has an understanding of corporate governance matters and experience with financial reporting and executive leadership that make him a valued member of our Board. Director Summary Compensation Table shows $93,625 fees paid in cash in 2015.
2017-04-28	Richard D. Peterson 49 2014 Chief Financial Officer of Sienna Biopharmaceuticals, Inc.; Formerly CFO of Novan, Inc. Nominating & Governance Committee member, Compensation Committee Chair, Audit Committee member, Director compensation $213,872
2018-04-27	Richard D. Peterson 50 2014 CFO of Dermavant Sciences, Inc.; Former CFO of Sienna Biopharmaceuticals, Inc. Nominating & Governance Committee member, Compensation Committee Chair, Audit Committee Chair
2019-04-29	Richard D. Petersonbecame a director of the Company in 2014. Mr. Peterson has over 20 years of experience in the areas of executive management, finance and accounting. Mr. Peterson served as the Chief Financial Officer of Dermavant Sciences, Inc., a position he held from 2018 to 2019. From 2017 to 2018, Mr. Peterson was the Chief Financial Officer of Sienna Biopharmaceuticals, Inc., a public pharmaceutical company. Mr. Peterson also served as Chief Financial Officer of Novan, Inc., a public pharmaceutical company,from 2015 to 2017. Mr. Peterson served in various executive roles at Medicis Pharmaceutical Corporation from 1995 to 2012, including as Executive Vice President, Chief Financial Officer and Treasurer from 2008 to 2012. Mr. Peterson has an understanding of corporate governance matters and experience with financial reporting and executive leadership that make him a valued member of our Board.
2020-04-29	Richard D. Peterson 52 2014 CFO of Botanix Pharmaceuticals Ltd. Member of Investment Committee, Chair of Compensation Committee. Total compensation $298,037.
2021-04-29	Richard D. Peterson 53 2014 CFO of Clarus Therapeutics. Committees: Member of Nominating & Governance, Chair of Compensation. Director Compensation: $100,000 in 2020.
2022-04-29	Richard D. Peterson became a director of the Company in 2014. Mr. Peterson has over 20 years of experience in the areas of executive management, finance and accounting. Since February 2021, Mr. Peterson has served as the Chief Financial Officer of Clarus Therapeutics, a specialty pharmaceutical company. Mr. Peterson has served as the Chief Financial Officer of various biotech companies from 2015 to 2020 including the publicly traded Botanix Pharmaceuticals, Sienna Biopharmaceuticals, Inc. and Novan, Inc. Mr. Peterson served in various executive roles at Medicis Pharmaceutical Corporation, a New York Stock Exchange (NYSE) listed company, from 1995 to 2012, including as Executive Vice President, Chief Financial Officer and Treasurer from 2008 to 2012. Mr. Peterson has an understanding of corporate governance matters and experience with financial reporting and executive leadership that make him a valued member of our Board. The table below summarizes the compensation paid to our independent directors for the fiscal year ended December 31, 2021. Richard D. Peterson received $100,000 in cash fees in 2021.
2023-04-28	Richard D. Peterson became a director of the Company in 2014. Mr. Peterson has over 20 years of experience in the areas of executive management, finance and accounting. Since September 2022, Mr. Peterson has served as Chief Financial Officer of Turn Biotechnologies, Inc., a private biotechnology company. Mr. Peterson previously served as the Chief Financial Officer of various biotech companies from 2015 to 2021, including the publicly traded Botanix Pharmaceuticals, Sienna Biopharmaceuticals, Inc. and Novan, Inc. Mr. Peterson served in various executive roles at Medicis Pharmaceutical Corporation, a New York Stock Exchange (“NYSE”) listed company, from 1995 to 2012, including as Executive Vice President, Chief Financial Officer and Treasurer from 2008 to 2012. Mr. Peterson has an understanding of corporate governance matters and experience with financial reporting and executive leadership that make him a valued member of our Board.
2024-04-26	Richard D. Peterson became a director of the Company in 2014. Mr. Peterson has over 20 years of experience in the areas of executive management, finance and accounting. Since 2022, Mr. Peterson has served as Chief Financial Officer of Turn Biotechnologies, Inc., a private biotechnology company. Mr. Peterson previously served as the Chief Financial Officer of various biotech companies from 2015 to 2021, including the publicly traded Botanix Pharmaceuticals, Sienna Biopharmaceuticals, Inc. and Novan, Inc. Mr. Peterson served in various executive roles at Medicis Pharmaceutical Corporation, a New York Stock Exchange (“NYSE”) listed company, from 1995 to 2012, including as Executive Vice President, Chief Financial Officer and Treasurer from 2008 to 2012. Mr. Peterson has an understanding of corporate governance matters and experience with financial reporting and executive leadership that make him a valued member of our Board.